Abstract
The efficacy and safety of immune-checkpoint inhibitors in non-small cell lung cancer patients with idiopathic pulmonary fibrosis (IPF) remain unknown. Herein, we describe the case of a 62-year-old man with multiple pleural tumors and carcinomatous pleurisy. High-resolution computed tomography indicated usual interstitial pneumonia, and a respiratory function test revealed a restrictive disorder and decreased diffusion capacity. He was diagnosed with lung adenocarcinoma and IPF. After failure of initial chemotherapy, he was treated with nivolumab and achieved a complete response without any sign of exacerbation of IPF. The response to nivolumab has persisted for > 1 year. This is the first report of a non-small cell lung cancer patient with IPF who has been treated with immune-checkpoint inhibitors for such a long period and achieved a sustained response.
| Original language | English |
|---|---|
| Pages (from-to) | 1519-1521 |
| Number of pages | 3 |
| Journal | Thoracic Cancer |
| Volume | 9 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - Nov 1 2018 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Pulmonary and Respiratory Medicine
Cite this
Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis. / Ide, Maako; Tanaka, Kentaro; Sunami, Shunya; Asoh, Tatsuma; Maeyama, Takashige; Tsuruta, Nobuko; Nakanishi, Yoichi; Okamoto, Isamu.
In: Thoracic Cancer, Vol. 9, No. 11, 01.11.2018, p. 1519-1521.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis
AU - Ide, Maako
AU - Tanaka, Kentaro
AU - Sunami, Shunya
AU - Asoh, Tatsuma
AU - Maeyama, Takashige
AU - Tsuruta, Nobuko
AU - Nakanishi, Yoichi
AU - Okamoto, Isamu
PY - 2018/11/1
Y1 - 2018/11/1
N2 - The efficacy and safety of immune-checkpoint inhibitors in non-small cell lung cancer patients with idiopathic pulmonary fibrosis (IPF) remain unknown. Herein, we describe the case of a 62-year-old man with multiple pleural tumors and carcinomatous pleurisy. High-resolution computed tomography indicated usual interstitial pneumonia, and a respiratory function test revealed a restrictive disorder and decreased diffusion capacity. He was diagnosed with lung adenocarcinoma and IPF. After failure of initial chemotherapy, he was treated with nivolumab and achieved a complete response without any sign of exacerbation of IPF. The response to nivolumab has persisted for > 1 year. This is the first report of a non-small cell lung cancer patient with IPF who has been treated with immune-checkpoint inhibitors for such a long period and achieved a sustained response.
AB - The efficacy and safety of immune-checkpoint inhibitors in non-small cell lung cancer patients with idiopathic pulmonary fibrosis (IPF) remain unknown. Herein, we describe the case of a 62-year-old man with multiple pleural tumors and carcinomatous pleurisy. High-resolution computed tomography indicated usual interstitial pneumonia, and a respiratory function test revealed a restrictive disorder and decreased diffusion capacity. He was diagnosed with lung adenocarcinoma and IPF. After failure of initial chemotherapy, he was treated with nivolumab and achieved a complete response without any sign of exacerbation of IPF. The response to nivolumab has persisted for > 1 year. This is the first report of a non-small cell lung cancer patient with IPF who has been treated with immune-checkpoint inhibitors for such a long period and achieved a sustained response.
UR - http://www.scopus.com/inward/record.url?scp=85052789668&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052789668&partnerID=8YFLogxK
U2 - 10.1111/1759-7714.12853
DO - 10.1111/1759-7714.12853
M3 - Article
VL - 9
SP - 1519
EP - 1521
JO - Thoracic Cancer
JF - Thoracic Cancer
SN - 1759-7706
IS - 11
ER -